[Heavy] Look at the history of the development of IVD giant Abbott diagnosis

Abbott has been in China for nearly 20 years, providing a wide range of nutritional, pharmaceutical and medical products to Chinese consumers. Currently, in addition to its China headquarters in Shanghai, Abbott has established 10 offices, 3 factories and 2 R&D centers with more than 4,000 employees.

Since 2010, Abbott has continued to invest in the Chinese market. Products developed, produced and distributed in China cover nutritional products, pharmaceuticals, medical devices and diagnostic products, ensuring that its products and services are fully compatible from disease prevention to diagnosis and treatment. The overall need for recovery. In 2014, Abbott invested US$230 million in the establishment of an advanced nutrition factory in Jiaxing. This is Abbott's largest investment project in China, demonstrating Abbott's strong intention to improve the health of all Chinese.

Abbott values ​​China's domestic R&D capabilities, not only to establish a research and development center in Shanghai, but also to establish a Shanghai Children's Medical Center with its partners. Through local clinical trials and operations, Abbott China's research and development capabilities have been greatly enhanced. In terms of medical innovation, Abbott works with other R&D centers around the world to address the world's medical challenges.

M&A situation

In 1888, Dr. Wallace Abbott founded the Abbott Pharmaceutical Factory in Chicago;

In 1923, Abbott entered the field of anesthesia;

In 1960, amino ethyl sulphate (taurine) was first added to infant formula;

In 2001, the acquisition of BA's Knoll Pharmaceuticals enhanced the research and development capabilities of immunology;

In 2002, Humira, (therapeutic rheumatoid arthritis) was approved by the US FDA;

In 2002, the company acquired Vysis and entered the field of molecular diagnostics;

In 2003, the acquisition of TheraSense Blood Glucose Products, Abbott's blood glucose monitoring system was more technologically advanced;

In 2008, SIMCOR was successfully launched;

In September 2012, Abbott announced that Abbott's intellectual training, jointly launched with the China Association for Eugenics and Children's Development, has benefited more than 500,000 families nationwide;

In July 2013, Abbott's $400 million acquisition of privately held OptiMedica to enter the cataract laser surgery business; and in another transaction to acquire stent manufacturer Idev Technologies for $310 million;

In April 2016, Abbott announced that it had agreed to acquire medical equipment manufacturer St. Jude Medical Corporation for approximately $25 billion.

Market performance

Figure 1: Performance of the Big Three in 2016 (announced in July 2016)

Figure 2: Abbott’s diagnostic business composition

With A Variety Of Side Dishes

Zhejiang Shanying Trading Co.,Ltd. , https://www.shanyingtrading.com